RRA
BDTX icon

Round Rock Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

Round Rock Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$584K Buy
274,367
+149,803
+120% +$356K 0.09% 178
2025
Q4 		$303K Buy
+124,564
New +$441K 0.05% 266

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Round Rock Advisors's BDTX Position: Q1 2026 in Review

Round Rock Advisors increased its Black Diamond Therapeutics (BDTX) stake by 120% in Q1 2026, buying an estimated $356K and bringing the position to 274,367 shares worth $584K. The position accounts for 0.09% of the portfolio, ranked #178.

Round Rock Advisors first reported a position in BDTX in Q4 2025 and has held it in 2 quarters since. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Round Rock Advisors held 274,367 shares of Black Diamond Therapeutics worth $584K as of Q1 2026.
  • Round Rock Advisors bought 149,803 Black Diamond Therapeutics shares in Q1 2026, an estimated $356K.
  • Black Diamond Therapeutics made up 0.09% of Round Rock Advisors's portfolio in Q1 2026, its #178 holding.
  • Round Rock Advisors first reported a position in Black Diamond Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Round Rock Advisors's 13F filing for Q1 2026, filed 15 May 2026.